Trial ID or NCT#

NCT00230282

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.

Official Title

A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Steven Coutre
Yasodha Natkunam, M.D., Ph.D
Yasodha Natkunam, M.D., Ph.D
Pathologist, Hematopathologist, Surgical pathologist, Immunodiagnosis pathologist
Ronald F. Dorfman, MBBch, FRCPath Professor of Hematopathology
Athena Cherry
James L. Zehnder, M.D.
James L. Zehnder, M.D.
Hematologist, Pathologist
Professor of Pathology (Research) and of Medicine (Hematology)

Contact us to find out if this trial is right for you.

CONTACT

Nini Estevez
(650) 725-4041